Literature DB >> 17310049

The effectiveness of a primer to help people understand risk: two randomized trials in distinct populations.

Steven Woloshin1, Lisa M Schwartz, H Gilbert Welch.   

Abstract

BACKGROUND: People need basic data interpretation skills to understand health risks and to weigh the harms and benefits of actions meant to reduce those risks. Although many studies document problems with understanding risk information, few assess ways to teach interpretation skills.
OBJECTIVE: To see whether a general education primer improves patients' medical data interpretation skills.
DESIGN: Two randomized, controlled trials done in populations with high and low socioeconomic status (SES).
SETTING: The high SES trial included persons who attended a public lecture series at Dartmouth Medical School, Hanover, New Hampshire; and the low SES trial included veterans and their families from the waiting areas at the White River Junction Veterans Affairs Medical Center, White River Junction, Vermont. PARTICIPANTS: 334 adults in the high SES trial and 221 veterans and their families in the low SES trial were enrolled from October 2004 to August 2005. Completion rates for the primer and control groups in each trial were 95% versus 98% (high SES) and 85% versus 96% (low SES). INTERVENTION: The intervention in the primer groups was an educational booklet specifically developed to teach people the skills needed to understand risk. The control groups received a general health booklet developed by the U.S. Department of Health and Human Services Agency for Health Care Research and Quality. MEASUREMENTS: Score on a medical data interpretation test, a previously validated 100-point scale, in which 75 points or more is considered "passing." Secondary outcomes included 2 other 100-point validated scores (interest and confidence in interpreting medical statistics) and participants' ratings of the booklet's usefulness.
RESULTS: In the high SES trial, 74% of participants in the primer group received a "passing grade" on the medical data interpretation test versus 56% in the control group (P = 0.001). Mean scores were 81 and 75, respectively (P = 0.0006). In the low SES trial, 44% versus 26% "passed" (P = 0.010): Mean scores were 69 and 62 in the primer and control groups, respectively (P = 0.008). The primer also significantly increased interest in medical statistics by 6 points in the high SES trial (a 4-point increase vs. a 2-point decrease from baseline) (P = 0.004) and by 8 points in the low SES trial (a 6-point increase vs. a 2-point decrease from baseline) (P = 0.004) compared with the control booklet. The primer, however, did not improve participants' confidence in interpreting medical statistics beyond the control booklet (a 2-point vs. a 4-point increase in the high SES trial [P = 0.36] and a 2-point versus a 6-point increase in the low SES trial [P = 0.166]). The primer was rated highly: 91% of participants in the high SES trial found it "helpful" or "very helpful," as did 95% of participants in the low SES trial. LIMITATIONS: The primarily male low SES sample and the primarily female high SES sample limits generalizability. The authors did not assess whether better data interpretation skills improved decision-making.
CONCLUSION: The primer improved medical data interpretation skills in people with high and low SES. ClinicalTrials.gov registration number: NCT00380432.

Entities:  

Mesh:

Year:  2007        PMID: 17310049     DOI: 10.7326/0003-4819-146-4-200702200-00004

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  17 in total

1.  Participation in mammography screening.

Authors:  Lisa M Schwartz; Steven Woloshin
Journal:  BMJ       Date:  2007-10-13

Review 2.  Lost in translation: helping patients understand the risks of inflammatory bowel disease therapy.

Authors:  Corey A Siegel
Journal:  Inflamm Bowel Dis       Date:  2010-12       Impact factor: 5.325

3.  Informed choice in bowel cancer screening: a qualitative study to explore how adults with lower education use decision aids.

Authors:  Sian K Smith; Paul Kearney; Lyndal Trevena; Alexandra Barratt; Don Nutbeam; Kirsten J McCaffery
Journal:  Health Expect       Date:  2012-04-19       Impact factor: 3.377

4.  Communication and decision making in cancer care: setting research priorities for decision support/patients' decision aids.

Authors:  Amber E Barnato; Hilary A Llewellyn-Thomas; Ellen M Peters; Laura Siminoff; E Dale Collins; Michael J Barry
Journal:  Med Decis Making       Date:  2007-09-14       Impact factor: 2.583

5.  Underuse of breast cancer adjuvant treatment: patient knowledge, beliefs, and medical mistrust.

Authors:  Nina A Bickell; Jessica Weidmann; Kezhen Fei; Jenny J Lin; Howard Leventhal
Journal:  J Clin Oncol       Date:  2009-09-21       Impact factor: 44.544

Review 6.  How numeracy influences risk comprehension and medical decision making.

Authors:  Valerie F Reyna; Wendy L Nelson; Paul K Han; Nathan F Dieckmann
Journal:  Psychol Bull       Date:  2009-11       Impact factor: 17.737

7.  The ethics of information: absolute risk reduction and patient understanding of screening.

Authors:  Peter H Schwartz; Eric M Meslin
Journal:  J Gen Intern Med       Date:  2008-04-18       Impact factor: 5.128

8.  Association between cancer risk perception and screening behavior among diverse women.

Authors:  Sue E Kim; Eliseo J Pérez-Stable; Sabrina Wong; Steve Gregorich; George F Sawaya; Judith M E Walsh; Celia P Kaplan
Journal:  Arch Intern Med       Date:  2008-04-14

9.  Numeracy and communication with patients: they are counting on us.

Authors:  Andrea J Apter; Michael K Paasche-Orlow; Janine T Remillard; Ian M Bennett; Elana Pearl Ben-Joseph; Rosanna M Batista; James Hyde; Rima E Rudd
Journal:  J Gen Intern Med       Date:  2008-10-02       Impact factor: 5.128

10.  Colorectal cancer knowledge is not associated with screening compliance or intention.

Authors:  David S Weinberg; Suzanne Miller; Michelle Rodoletz; Brian Egleston; Linda Fleisher; Joanne Buzaglo; Eileen Keenan; Jaime Marks; Eric Bieber
Journal:  J Cancer Educ       Date:  2009       Impact factor: 2.037

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.